Company logo

PCVX - Vaxcyte, Inc.

NASDAQ -> Healthcare -> Biotechnology
San Carlos, United States
Type: Equity

PCVX price evolution
PCVX
(in millions $) 30 Jun 2024 31 Mar 2024 31 Dec 2023 30 Sep 2023
Current assets
Cash $518.67 $611.51 $397.45 $545.13
Short term investments $934.03 $875.01 $682.78 $720.55
Net receivables
Inventory
Total current assets $1481.48 $1517.07 $1095.95 $1295.43
Long term investments $400.35 $414.35 $163.78 $169.67
Property, plant & equipment $152.75 $113.74 $110.62 $27.76
Goodwill & intangible assets
Total noncurrent assets $605.79 $574.23 $311.96 $200.62
Total investments $1334.37 $1289.36 $846.55 $890.22
Total assets $2087.27 $2091.3 $1407.92 $1496.06
Current liabilities
Accounts payable $10.47 $21.72 $14.59 $15.7
Deferred revenue
Short long term debt $7.29 $7.2 $7.11 $6.03
Total current liabilities $82.85 $87.1 $145.34 $85.56
Long term debt $18.29 $20.22 $22.11 $7.78
Total noncurrent liabilities $18.29 $20.22 $22.11 $7.78
Total debt $25.58 $27.42 $29.22 $13.81
Total liabilities $101.14 $107.32 $167.45 $93.34
Shareholders' equity
Retained earnings -$1148.12 -$1019.41 -$924.39 -$743.59
Other shareholder equity $1.81 $2.89 $0.18 -$2.29
Total shareholder equity $1986.13 $1983.98 $1240.47 $1402.72
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $397.45 $834.66 $68.98 $386.2
Short term investments $682.78 $96.72 $176.99
Net receivables
Inventory
Total current assets $1095.95 $942.55 $256.35 $389
Long term investments $163.78 $27.42 $27.99
Property, plant & equipment $110.62 $31.65 $35.91 $3.27
Goodwill & intangible assets
Total noncurrent assets $311.96 $63.62 $67.99 $3.82
Total investments $846.55 $124.14 $204.97
Total assets $1407.92 $1006.18 $324.34 $392.83
Current liabilities
Accounts payable $14.59 $9.79 $6.76 $29.79
Deferred revenue
Short long term debt $7.11 $5.91 $5.28
Total current liabilities $145.34 $40.52 $28.72 $46.86
Long term debt $22.11 $12.03 $11.51
Total noncurrent liabilities $22.11 $12.04 $11.6 $0.12
Total debt $29.22 $17.94 $16.78
Total liabilities $167.45 $52.56 $40.32 $46.98
Shareholders' equity
Retained earnings -$924.39 -$522.13 -$298.64 -$198.56
Other shareholder equity $0.18 -$0.36 -$0.24
Total shareholder equity $1240.47 $953.61 $284.02 $345.84
(in millions $) 30 Jun 2024 31 Mar 2024 31 Dec 2023 30 Sep 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $131.51 $94.59 $104.15 $97.42
Selling, general & administrative $21.47 $19.89 $17.53 $15.61
Total operating expenses $152.98 $114.47 $196.68 $113.03
Operating income -$152.98 -$114.47 -$196.68 -$113.03
Income from continuing operations
EBIT -$128.7 -$95.02 -$180.8 -$92.66
Income tax expense
Interest expense
Net income
Net income -$128.7 -$95.02 -$180.8 -$92.66
Income (for common shares) -$128.7 -$95.02 -$180.8 -$92.66
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $332.34 $169.45 $78.41 $73.56
Selling, general & administrative $60.7 $39.81 $25.26 $16.02
Total operating expenses $468.04 $232.26 $103.67 $89.58
Operating income -$468.04 -$232.26 -$103.67 -$89.58
Income from continuing operations
EBIT -$402.27 -$223.48 -$100.07 -$89.21
Income tax expense
Interest expense $0 $0.01 $0.01
Net income
Net income -$402.27 -$223.49 -$100.08 -$89.22
Income (for common shares) -$402.27 -$223.49 -$100.08 -$89.22
(in millions $) 30 Jun 2024 31 Mar 2024 31 Dec 2023 30 Sep 2023
Net income -$128.7 -$95.02 -$180.8 -$92.66
Operating activities
Depreciation $3.48 $3.09 $2.95 $2.48
Business acquisitions & disposals
Stock-based compensation $21.56 $17.63 $13.35 $13.22
Total cash flows from operations -$121.39 -$159.12 -$128.81 -$57.55
Investing activities
Capital expenditures -$38.98 -$12.07 -$57.07 -$7.34
Investments -$41.43 -$439 $43.14 $29.62
Total cash flows from investing -$80.41 -$451.07 -$13.93 $22.28
Financing activities
Dividends paid
Sale and purchase of stock $110.37 $818.2 $2.73 $48.55
Net borrowings
Total cash flows from financing $110.37 $818.2 $2.73 $48.55
Effect of exchange rate -$1.41 $6.06 -$7.68 $1.05
Change in cash and equivalents -$92.84 $214.06 -$147.68 $14.33
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$402.27 -$223.49 -$100.08 -$89.22
Operating activities
Depreciation $10.17 $9.2 $3.46 $1.41
Business acquisitions & disposals
Stock-based compensation $48.76 $23.65 $10.73 $5.43
Total cash flows from operations -$296.79 -$170.6 -$121.39 -$46.63
Investing activities
Capital expenditures -$67.88 -$5.84 -$6.53 -$1.1
Investments -$705.43 $80.43 -$205.78
Total cash flows from investing -$773.31 $74.58 -$212.31 -$1.1
Financing activities
Dividends paid
Sale and purchase of stock $639.81 $862.41 $17.8 $268.42
Net borrowings -$0.06
Total cash flows from financing $639.81 $861.55 $17.8 $374.87
Effect of exchange rate -$6.69 $0.14 -$0.44 $0.09
Change in cash and equivalents -$436.97 $765.67 -$316.34 $327.22
Fundamentals
Market cap $12.95B
Enterprise value $12.46B
Shares outstanding 110.58M
Revenue $0.00
EBITDA -$485.19M
EBIT -$497.19M
Net Income -$497.19M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -26.05
EV/Sales N/A
EV/EBITDA -25.68
EV/EBIT -25.06
P/S ratio N/A
P/B ratio 6.53
Book/Share 17.95
Cash/Share 4.69
EPS -$4.50
ROA -28.08%
ROE -30.07%
Debt/Equity 0.13
Net debt/EBITDA 0.86
Current ratio 17.88
Quick ratio 17.88